Stable Gene Transfer to Muscle Using Non-integrating Lentiviral Vectors
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Human immunodeficiency virus (HIV)-based lentiviral vectors (LVs) hold immense promise for gene delivery applications because of their relatively large packaging capacity and their ability to infect a range of cell types. The genome of HIV non-specifically integrates into the host genome, and this promotes efficient, stable transgene expression in dividing cells. However, integration can also be problematic because of variations in gene expression among cells, possible gene silencing and, most importantly, insertional mutagenesis which can lead to undesirable effects such as malignant transformation. In order to alleviate these problems, we have developed a range of non-integrating LVs (NILVs) by introducing point mutations into the catalytic site, chromosome binding site, and viral DNA binding site of the viral integrase (IN). In addition, we have mutated the IN attachment (att) sites within the HIV long terminal repeats (LTRs). All of the vectors produced show efficient reverse transcription and transgene expression in dividing cells and prolonged expression in non-dividing myotubes. Finally, we show that NILV can be used for achieving highly effective gene transfer and expression in muscle in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Any alterations to these amino acids will inactivate the catalytic activity of IN and inhibit the integration while preserving the transgene expression [20,29,30].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [20]
In the citing paper
“A non-integrating LV was engineered to avoid unwanted integration. In these vectors, selected mutations were induced within the integrase coding region to eliminate the integrase activities without affecting reverse transcription and transport of the pre-integrating complex into the nucleus [48,49,50].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [50]
Citations
Cites
A simple salting out procedure for extracting DNA from human nucleated cells
Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.3.1215 · Cited by 20,330
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., & Yee, J. K. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8033 · Cited by 1,399
A quantitative assay for HIV DNA integration in vivo
Butler, S. L., Hansen, M. S. T., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 687 · cited 1×
“(a) Integrase domains: bold font represents conserved amino acids [Zinc (Zn) finger (HHCC) and catalytic core (DD(35)E], mutated residues are underlined.”
BackgroundDemaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., Grez, M., & Thrasher, A. J. (2002) · Human Gene Therapy · doi:10.1089/10430340252898984 · Cited by 486
Self-citationGallay, P., Hope, T., Chin, D., & Trono, D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9825 · Cited by 485
Effective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460
Self-citationBrown, P. O., Bowerman, B., Varmus, H. E., & Bishop, J. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.8.2525 · Cited by 399
Cited by
Items 101–177 of 177
Nonintegrating Foamy Virus Vectors
Deyle, D. R., Li, Y., Olson, E. M., & Russell, D. W. (2010) · Journal of Virology · doi:10.1128/jvi.00394-10 · Cited by 21
“After infection, nonintegrating vector genomes are found as linear, 1-long-terminal-repeat (1-LTR), or 2-LTR episomal DNA molecules and are stable, but because these episomes do not replicate, they are diluted over time in proliferating cells (1, 5, 7, 41).”
BackgroundMethodPerinatal Gene Transfer to the Liver
McKay, T. R., Rahim, A. A., Buckley, S. M. K., Ward, N. J., Chan, J. K. Y., Howe, S. J., & Waddington, S. N. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797247541 · Cited by 20
“However, to date, following several studies where many mice were injected in utero and neonatally by these routes with HIVbased lentivirus we have observed no increase, over background, in the incidence of hepatocellular carcinoma [34, 67, 148].”
BackgroundSelf-citationTargeting Lentiviral Vectors for Cancer Immunotherapy
Vargas, F. A., Breckpot, K., Collins, M. K., & Escors, D. (2011) · Current Cancer Therapy Reviews · doi:10.2174/157339411797642605 · Cited by 19
Self-citationFontana, J. M., Christos, P. J., Michelini, Z., Negri, D. R. M., Cara, A., & Salvatore, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097270 · Cited by 18
“of study) after administration in muscle [15].”
Alex, S. M., & Sharma, C. P. (2012) · Drug Delivery and Translational Research · doi:10.1007/s13346-012-0120-0 · Cited by 18
“Gene delivery has been developed with viruses such as adeno-associated virus (AAV), which has its virulent genes removed [2] and with lentiviruses [3], clearly stating their efficiency.”
MethodGrandchamp, N., Henriot, D., Philippe, S., Amar, L., Ursulet, S., Serguera, C., Mallet, J. J., & Sarkis, C. (2011) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-9-1 · Cited by 19
“However, transgene expression from such vectors may be 2 to 10 times less strong than that from otherwise similar integrative control vectors [1,30,36,37].”
BackgroundQasim, W., Vink, C. A., & Thrasher, A. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.76 · Cited by 19
Self-citationDesigning Lentiviral Gene Vectors
Tolmachov, O. E., Tolmachova, T., & Al-Allaf, F. A. (2011) · InTech eBooks · doi:10.5772/17361 · Cited by 22
“…random chromosomal integration of their proviruses (Nightingale, Hollis et al. 2006; Philippe, Sarkis et al. 2006; Yanez-Munoz, Balaggan et al. 2006; Apolonia, Waddington et al. 2007; Philpott and Thrasher 2007; Bayer, Kantor et al. 2008; Sarkis, Philippe et al. 2008; Rahim, Wong et al. 2009).”
BackgroundGene Therapy - Developments and Future Perspectives
Kang, C. (2011) · InTech eBooks · doi:10.5772/748 · Cited by 16
Integrase Defective, Nonintegrating Lentiviral Vectors
Michelini, Z., Negri, D. R. M., & Cara, A. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-533-0_6 · Cited by 18
Tarakanchikova, Y. V., Muslimov, A. R., Zyuzin, M. V., Nazarenko, I. A., Timin, A. S., Sukhorukov, G. B., & Lepik, K. V. (2020) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.202000228 · Cited by 16
Rossi, A., Michelini, Z., Leone, P., Borghi, M., Blasi, M., Bona, R., Spada, M., Grasso, F., Gugliotta, A., Klotman, M. E., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107377 · Cited by 16
“This is in agreement with reports showing that IDLV persists up to 9 months from the inoculum in non-dividing cells or tissues [45–49].”
ResultShi, Y., Weng, W., Chen, M., Huang, H., Chen, X., Peng, Y., & Hu, Y. (2023) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2023.106685 · Cited by 15
“Random genome integration in muscle cells has the risk of insertional mutagenesis, which is considered to be unsafe even in post-mitotic tissues [45].”
BackgroundHu, P., Li, Y., Sands, M. S., McCown, T. J., & Kafri, T. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.25 · Cited by 15
On the development of optical peripheral nerve interfaces
Anderson, H., & Weir, R. F. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.245461 · Cited by 14
“post-mitotic cells (Apolonia et al., 2007), and have similar”
BackgroundPrimary Murine Myotubes as a Model for Investigating Muscular Dystrophy
Smolina, N., Kostareva, A. A., Bruton, J. D., Karpushev, A. V., Sjöberg, G., & Sejersen, T. (2015) · BioMed Research International · doi:10.1155/2015/594751 · Cited by 16
Irwan, I. D., & Cullen, B. R. (2021) · Journal of Virology · doi:10.1128/jvi.00285-21 · Cited by 15
Retrovirus-based vectors for transient and permanent cell modification
Schott, J. W., Hoffmann, D., & Schambach, A. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.004 · Cited by 13
Chen, J., Zhang, Q., Tan, J., He, T., Qin, B., Sheng, N., Zhang, H., & Xie, H. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.154333 · Cited by 17
Watters, S. A., Mlčochová, P., Maldarelli, F. M., Goonetilleke, N. P., Pillay, D., & Gupta, R. K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158854 · Cited by 11
“HIV-1 RNA and total HIV-1 DNA were quantified as previously described [10, 26].”
MethodSaida, H., Matsuzaki, Y., Takayama, K., Iizuka, A., Konno, A., Yanagi, S., & Hirai, H. (2014) · Gene Therapy · doi:10.1038/gt.2014.60 · Cited by 13
Gene Delivery and Expression Systems in Induced Pluripotent Stem Cells
Zhang, M., Niibe, K., Kondo, T., Kamano, Y., Saeki, M., & Egusa, H. (2016) · Springer eBooks · doi:10.1007/978-981-10-1560-1_11 · Cited by 13
Shaw, A., Joseph, G. L., Jasti, A. C., Sastry, L., Witting, S. R., & Cornetta, K. G. (2016) · Gene Therapy · doi:10.1038/gt.2016.69 · Cited by 11
Counsell, J. R., Karda, R., Diaz, J. F. A., Carey, L., Wiktorowicz, T., Buckley, S. M. K., Ameri, S., Ng, J., Baruteau, J., Almeida, F., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.07.006 · Cited by 12
Self-citationXie, R., He, W., Shen, M., Shou, X., Wang, Y., Bao, W.-M., & Zhao, Y. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1895-x · Cited by 9
Emerging applications of lentiviral vectors in dendritic cell-based immunotherapy
Wang, H., Zhang, L. N., & Kung, S. K. P. (2010) · Immunotherapy · doi:10.2217/imt.10.44 · Cited by 9
Lentiviral vector-based therapy in head and neck cancer (Review)
Upreti, D., Pathak, A., & Kung, S. K. P. (2013) · Oncology Letters · doi:10.3892/ol.2013.1652 · Cited by 11
“In applications that do not require long-term stable gene expression, integration‐deficient lentiviral vectors (that harbor class I mutations of the HIV-1 integrase) for transient transgene expression may also provide a safer alternative to the current lentiviral-based therapies (105-108).”
BackgroundZhang, W., Chen, H., Zheng, X., Wang, D., Ji, H., Xia, H., & Mao, Q. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.08.003 · Cited by 8
Advancement and Applications of Platelet-inspired Nanoparticles: A Paradigm for Cancer Targeting
Swain, S., Ghose, D., Patra, C. N., Jena, B. R., & Rao, M. E. B. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023666220329111920 · Cited by 8
Cortijo-Gutierréz, M., Sánchez-Hernández, S., Tristán‐Manzano, M., Maldonado‐Pérez, N., López-Onieva, L., Real, P. J., Herrera, C., Marchal, J. A., Martín, F., & Benabdellah, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081217 · Cited by 8
Nordin, F., Hamid, Z. A., Chan, L., Farzaneh, F., & Hamid, M. K. A. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3753-0_12 · Cited by 7
Ma, S., Lv, M., Chen, X., Zang, G., Tang, Z., Zhang, Y., & Hu, W. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105662 · Cited by 7
Integrase-Defective Lentiviral Vectors for Delivery of Monoclonal Antibodies against Influenza
Michelini, Z., Minkoff, J. M., Yang, J., Negri, D., Cara, A., Hanson, B. J., & Salvatore, M. (2020) · Viruses · doi:10.3390/v12121460 · Cited by 6
“In fact, IDLV have a mutation in their integrase coding sequence that blocks DNA integration, thereby drastically reducing the risk of unintentional insertion of the vector into a critical host gene during treatment, while still maintaining high transduction efficiency [7].”
BackgroundLentiviral Vectors for Gene Delivery to the Nervous System
Eleftheriadou, I., & Mazarakis, N. D. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_2 · Cited by 6
Induced pluripotent stem cell (iPS) technology: promises and challenges
Esteban, M. A., Gan, Y., Qin, D., & Pei, D. (2009) · Chinese Science Bulletin · doi:10.1007/s11434-009-0014-9 · Cited by 5
Wu, H., Chaudhary, A., & Mahato, R. I. (2019) · Springer eBooks · doi:10.1007/978-3-030-00710-2_16 · Cited by 5
Flynn, R. P., Zacharias, J., Zhou, X., Cannon, M. L., & Philpott, N. J. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1601 · Cited by 4
“With a view towards clinical applications and avoiding the risks associated with insertional mutagenesis, we have used non-integrating lentiviral vectors (NILVs) to achieve high transduction of B cells [18].”
BackgroundMethodSelf-citationRecent Advances and Improvements in the Biosafety of Gene Therapy
Sivalingam, J., & Lian, O. (2011) · InTech eBooks · doi:10.5772/21733 · Cited by 3
“…domains have been more widely studied and reported to reduce residual integrase activity by 100- to 1000-fold compared with wild-type vectors (Apolonia et al., 2007) but with uncompromised transgene expression in vivo and about 2- to 10-fold decrease in expression in vitro (Apolonia et al., 2007).”
BackgroundInfluentialWu, H., & Mahato, R. I. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6486-0_24 · Cited by 3
Episomal Vectors: Principle, Utility, and Application
Sato, M., Inada, E., Watanabe, S., Saitoh, I., Kubota, N., Iwase, Y., Morohoshi, K., & Nakamura, S. (2025) · OBM Genetics · doi:10.21926/obm.genet.2504317 · Cited by 2
In vivo engineering of immunosuppressive T cells to treat ocular autoimmune diseases
Wang, D., Ling, J., Liang, J.-J., Li, J. W., Hu, Q., Yang, L., Jin, J., Bai, X., Zheng, Y., Lin, B., et al. (2026) · Experimental Eye Research · doi:10.1016/j.exer.2026.111041 · Cited by 2
HIV-1 signalling remodels nuclear pores to licence infection
Mesner, D., Whelan, M. V. X., Shivkumar, M., Reuschl, A., Chiozzi, R. Z., Thalassinos, K., de Bruin, R. A. M., & Jolly, C. L. (2026) · Nature · doi:10.1038/s41586-026-10453-3 · Cited by 3
“2-LTR circles were quantified using primers for the 2-LTR junction 58 . qPCR products were quantified using TaqMan Gene Expression Master Mix (Thermo Fisher Scientific) and the 7500 Real-Time PCR System (Applied Biosystems), using the following primers: RU5-forward: 5′-GCCTCAATAAAGCTTGCCTTGA;…”
Dendritic Cells and Lentiviral Vectors: Mapping the Way to Successful Immuno Gene Therapy
Goyvaerts, C., Kochan, G. T., Escors, D., & Breckpot, K. (2011) · InTech eBooks · doi:10.5772/17367 · Cited by 2
“Downsides are the lower titers, higher doses needed and the fact that there still is a chance for integration of about 0.1 to 2.3% (Apolonia et al. 2007).”
InfluentialTakayama, K., & Torashima, T. (2009) · Journal of NeuroVirology · doi:10.3109/13550280903214091 · Cited by 2
Lu‐Nguyen, N., Broadstock, M., & Yáñez‐Muñoz, R. J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3753-0_13 · Cited by 2
Assessment of Integration-defective HIV-1 and EIAV Vectors In Vitro and In Vivo
Ellis, S., Fong-Wong, L., Iqball, S., Thoree, V., Mitrophanous, K. A., & Binley, K. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.53 · Cited by 2
Deliverable transgenics & gene therapy possibilities for the testes
Darbey, A. L., & Smith, L. B. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.11.023 · Cited by 4
scFv Cloning, Vectors, and CAR-T Production in Laboratory for Preclinical Applications
Balkhi, M. Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819573-4.00003-x · Cited by 2
Michelini, Z., Negri, D. R. M., Biava, M., Baroncelli, S., Spada, M., Leone, P., Bona, R., Blasi, M., Négre, D., Klotman, M. E., et al. (2014) · Viral Immunology · doi:10.1089/vim.2014.0062 · Cited by 1
“Studies performed in vivo confirmed that the IDLV stably transduces nondividing cells, such as brain cells (35), ocular cells (49), and muscle cells (2), representing an encouraging alternative to their IN-competent counterpart, reducing potential events of insertional mutagenesis (45).”
Development of Retroviral and Lentiviral Vectors
Escors, D., Kochan, G. T., Stephenson, H. N., & Breckpot, K. (2012) · SpringerBriefs in biochemistry and molecular biology · doi:10.1007/978-3-0348-0402-8_2 · Cited by 1
Viral Technology for Delivery of Nucleic Acids
Bahrami, S., & Pedersen, F. S. (2009) · Wiley eBooks · doi:10.1002/9780470688397.ch5 · Cited by 1
Vaccines & Vaccine Technologies
(2014) · OMICS International eBooks · doi:10.4172/978-1-63278-004-1-005 · Cited by 1
Delivery Methods for CRISPR/Cas Reagents
Ashraf, S., Munawar, N., Zahoor, M. K., Jamil, A., Hammad, M., Ghaffar, A., & Ahmad, A. (2021) · Springer eBooks · doi:10.1007/978-981-16-6305-5_4 · Cited by 2
Development of targeted gene delivery vectors to assess cardiac overexpresion of ACE2 in vivo
Shirley, R. (2008) · Enlighten: Theses (The University of Glasgow) · Cited by 3
Gene Delivery to Cardiovascular Tissue
Masson, R., Nicklin, S. A., & Baker, A. H. (2009) · Springer eBooks · doi:10.1007/978-1-84882-637-3_2 · Cited by 1
Zhao, J., Tan, B., Chen, G., Du, Z., Yuan, Q., Yu, J., Sun, Y., Li, X., Hu, J., & Xie, R. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3559529 · Cited by 1
Askou, A. L., & Corydon, T. J. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2389-2_3
Robust Adaptive Control of Switched Systems
El, K., & Youcef‐Toumi, K. (2009) · InTech eBooks · doi:10.5772/7041
Karwacz, K. (2012) · UCL Discovery (University College London)
Panakanti, R. (2010) · doi:10.21007/etd.cghs.2010.0236
“To alleviate this effect non-integrating lentiviral vectors are developed by point mutations into the chromosome binding site, the viral DNA binding site of the viral integrase.(81)”
BackgroundAssessing the potential of non-integrating lentiviral vectors for cardiovascular gene therapy
Chick, H. E. (2011) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.3045
Factors affecting the formation, stability, and expression of unintegrated lentiviral vector genomes
Bayer, M. (2010) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/j9mp-1c47
The Toughest Nut to Crack: Will We Ever Have a Preventive and Effective HIV-1 Vaccine?
Berneman, Z. N. (2016) · Molecular Therapy · doi:10.1038/mt.2016.195
MDS1/EVI1 and PRDM16 deregulation in hematopoiesis after experimental and clinical gene transfer
Wang, W. (2012) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00013202
Cockrell, A. S. (2011) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/t9n9-ct90
Role of Retroviral vector-based Interventions in Combating Virus Infections
Khanna, M., Manocha, N., Himanshi, Joshi, G., Saxena, L., & Saini, S. (2019) · Future Virology · doi:10.2217/fvl-2018-0151
Optimisation of lentiviral vectors for gene therapy of spinal muscular atrophy
Nafchi, N. A. M. (2017)
Weber‐Adrian, D. (2017) · TSpace (University of Toronto)
Engineered genetic tools for directed gene regulation
Ferreira, R. R. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8703
Viral vectors for CNS disorders
Gray, S. J., Samulski, R. J., & Kalburgi, S. N. (2015) · doi:10.4155/fseb2013.13.23
An RNAi-Enhanced Logic Circuit for Cancer Specific Detection and Destruction
Weiss, R., Wróblewska, L., & Xie, Z. (2013) · Defense Technical Information Center (DTIC) · doi:10.21236/ada582947
Zhang, F., Lu, Q., Qian, X., Xing, Y., & Wang, W. (2025) · Biochemical Genetics · doi:10.1007/s10528-025-11300-2
“Notably, this mutation does not affect viral production, reverse transcription, nuclear import, or transgene expression (Apolonia et al. 2007).”
InfluentialLentiviral vectors for treatment of haemophilia
Ward, N. J. (2010) · UCL Discovery (University College London)
Self-citationGene Therapy for Nonneoplastic Hematologic and Histiocytic Disorders
Washington, K. N., Tisdale, J. F., & Hsieh, M. M. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-5698-9_45
Establishing and Utilising In Vitro Lung Models to Demonstrate Peptide Mediated Non-Viral Delivery
Smith, L. (2022) · Nottingham ePrints (University of Nottingham)
Renaud-Gabardos, E. (2016) · theses.fr (ABES) · doi:10.70675/6d9b4309za1adz4f4aza374zddc5391a757f
Metadata
- Authors
- Apolonia, L., Waddington, S. N., Fernandes, C., Ward, N. J., Bouma, G., Blundell, M. P., Thrasher, A. J., Collins, M. K., & Philpott, N. J.
- Affiliations
- Great Ormond Street Hospital (GB)
- The Royal Free Hospital (GB)
- University College London (GB)
- Corresponding author
- Philpott, Nicola J
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2007-11
- Volume
- 15
- Issue
- 11
- Pages
- 1947-1954
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2075291405
- Semantic Scholar
- 850dac0bd2562c1b020bdefb90da8572837bc426
- Cited by
- 174
- References
- 44
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 6 · 2020: 8 · 2019: 6 · 2018: 4 · 2017: 8 · 2016: 15 · 2015: 12 · 2014: 12 · 2013: 10 · 2012: 12
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3263 d)
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust
- Biotechnology and Biological Sciences Research Council
- Fundação para a Ciência e a Tecnologia
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- HIV-based vectors, insertional mutagenesis, myotubes, transgene expression, long terminal repeat, reverse transcription, in vivo gene delivery
- MeSH terms
- Animals, Cell Line, DNA, Viral, Genetic Vectors, Humans, Muscles, Mutation, Transduction, Genetic, Gene Expression, Lentivirus, Genome, Viral, Transgenes, Integrases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.